Results 11 to 20 of about 31,034 (262)

Treatments for dry age-related macular degeneration and Stargardt disease: a systematic review [PDF]

Health Technology Assessment, 2018
Background: Age-related macular degeneration (AMD) is the leading cause of visual loss in older people. Advanced AMD takes two forms, neovascular (wet) and atrophic (dry).
Norman Waugh, Emma Loveman, Jill Colquitt, Pamela Royle, Jian Lee Yeong, Geraldine Hoad, Noemi Lois   +6 more
doaj   +4 more sources

Human retinal organoids for modelling dry age-related macular degeneration and screening drugs [PDF]

Genes and Diseases
Age-related macular degeneration (AMD) poses a significant threat to the vision of the elderly population globally. Unfortunately, there is no effective treatment available for dry AMD.
Xiaolu Hao, Lu Du, Guang Liu, Zhaohui Li, Shaojun Wang   +4 more
doaj   +2 more sources

Nutrient supplementation for age-related macular degeneration, cataract, and dry eye

Journal of Ophthalmic & Vision Research, 2014
There have been enormous advances in the past decade for the treatment of age-related macular degeneration (AMD); however, these treatments are expensive and require frequent follow-up and injections which place a tremendous burden on both the healthcare
Ronald P Hobbs, Paul S Bernstein
doaj   +3 more sources

Optical Coherence Tomography Angiography of Dry Age-Related Macular Degeneration [PDF]

, 2016
Optical coherence tomography angiography (OCTA) can be used to visualize alterations in the choriocapillaris of patients with dry age-related macular degeneration (AMD). These changes seem to be present during all stages of the disease. Earlier stages are associated with patchy thinning of the choriocapillaris, while geographic atrophy is associated ...
Nadia K. Waheed, Eric M. Moult, James G. Fujimoto, Philip J. Rosenfeld   +3 more
openalex   +3 more sources

Dry and neovascular “wet” age-related macular degeneration: Upcoming therapies

Indian Journal of Ophthalmology
The age-related macular degeneration (AMD) field is witnessing promising advancements in therapeutic options. Breakthrough drugs such as pegcetacoplan and avacincaptad have been FDA-approved for dry AMD, marking a significant development as there were no
Audrey Yan, Nasiq Hasan, Jay Chhablani
doaj   +3 more sources

A Response to: Letter to the Editor Regarding "Safety, Tolerability, and Short-Term Efficacy of Low-Level Light Therapy for Dry Age-Related Macular Degeneration". [PDF]

Ophthalmol Ther
Borrelli E, Coco G, Scorcia V, Carnevali A, Reibaldi M, Giannaccare G.   +5 more
europepmc   +3 more sources

Safety and tolerability of RPESC-RPE transplantation in patients with dry age-related macular degeneration: Low-dose clinical outcomes. [PDF]

Cell Stem Cell
Rao RC, Arduini BL, Borden S, Sareen D, Svendsen C, Lee P, Ryan C, Kodati S, Nyaiburi C, Wolsieffer K, Oh E, Park S, Ford G, Dionne K, Temple S, Stern J.   +15 more
europepmc   +2 more sources

Adaptive Optics-Transscleral Flood Illumination Imaging of Retinal Pigment Epithelium in Dry Age-Related Macular Degeneration. [PDF]

Cells
Kowalczuk L, Dornier R, Navarro A, Jeunet F, Moser C, Behar-Cohen F, Mantel I.   +6 more
europepmc   +3 more sources

Caffeine intake and late dry age-related macular degeneration: tea's protective role-insights from NHANES and Mendelian randomization. [PDF]

Int J Retina Vitreous
Yang H, Liu B, Zhang Y, Zhang Z, Tan H, Li X.   +5 more
europepmc   +2 more sources

Dry age-related macular degeneration - therapeutic possibilities and research directions [PDF]

Farmacja Polska, 2022
Age-related macular degeneration (AMD) is a major cause of vision loss in developed countries, especially in the elderly population. AMD is a multifactorial disease which etiology is not completely understood.
Alicja Zajdel
doaj   +1 more source